Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Locust Walk","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Locust Walk"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Hyloris Pharmaceuticals"}]

Find Drugs for Dental and Oral Health in Phase III Clinical Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.

            Lead Product(s): Tranexamic Acid

            Therapeutic Area: Dental and Oral Health Product Name: Tranexamic Acid Oral Rinse

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 14, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Locust Walk

            Contact Supplier
            • Deals
            Virtual Booth Virtual Booth
            Digital Content Digital Content

            Details:

            This renewed engagement is a continuation of Innovation Pharmaceutical’s business relationship with Locust Walk toward realizing the market potential of the Company’s pipeline.

            Lead Product(s): Brilacidin

            Therapeutic Area: Dental and Oral Health Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Innovation Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY